Effect of Fruit and Vegetable Concentrates on Endothelial Function in Persons With Metabolic Syndrome

Effect of Fruit and Vegetable Concentrates on Endothelial Function in Persons With Metabolic Syndrome: A Randomized, Controlled, Crossover Trial

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01224743

Enrollment

Registered

2010-10-20

Start date

2004-12-31

Completion date

2008-03-31

Last updated

2020-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome

Brief summary

Dehydrated fruit and vegetable concentrates provide an accessible form of phytonutrient supplementation that may offer cardioprotective effects. This study assessed the effects of encapsulated fruit and vegetable juice powder concentrates on endothelial function and cardiac risk markers in subjects in a randomized, double blind, placebo controlled crossover clinical trial with three treatment arms.

Interventions

DIETARY_SUPPLEMENTBlend 1

Blend 1 consists of a combination of Juice Plus+® Orchard (Fruit), Garden (Vegetable), and Vineyard (Berry) blends

DIETARY_SUPPLEMENTBlend 2

Blend 2 consists of a combination of Juice Plus+® Orchard (Fruit) and Garden (Vegetable) blends

DIETARY_SUPPLEMENTPlacebo

Placebo capsules are provided by the study sponsor and are identical in appearance to active treatments to ensure blinding.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* metabolic syndrome defined by AHA/NHLBI criteria * nonsmoker * not taking any other vitamins or dietary supplements * able to have blood pressure measured bilaterally at the brachial artery

Exclusion criteria

* any unstable medical condition that would limit the ability to participate fully in the trial * rheumatologic disease requiring regular use of NSAIDs * preexisting cardiovascular disease * diagnosed eating disorder * inability to complete endothelial function assessment. * use of insulin, glucose sensitizing medication, vasoactive medications (including glucocorticoids, antineoplastic agents, psychoactive agents, or bronchodilators), nutriceuticals, fiber supplements, and tobacco.

Design outcomes

Primary

Measure	Time frame	Description
Endothelial Function	8-weeks	Endothelial function as flow-mediated dilatation (FMD)

Secondary

Measure	Time frame	Description
Weight	8-weeks	Measured on a calibrated scale
Lipid panel	8-weeks	Total cholesterol, TG, HDL, LDL, ratio
Insulin	8-weeks	Serum insulin

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026